Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ENTO

Entero Therapeutics Inc

Dec 13 • 04:00PM ET

0.5839

Dollar change -0.0428
Percentage change -6.83	%

Healthcare • Biotechnology • USA • NASD

Peers: VNDA LGND RARE PBYI XENE CENTA GLYC PTGX PRTA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.73	Insider Own	1.99%	Shs Outstand	4.74M	Perf Week	-26.94%
Market Cap	2.59M	Forward P/E	-	EPS next Y	-	Insider Trans	-2.63%	Shs Float	4.66M	Perf Month	-7.32%
Income	-10.19M	PEG	-	EPS next Q	-	Inst Own	1.96%	Short Float	1.47%	Perf Quarter	59.49%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-35.40%	Short Ratio	0.15	Perf Half Y	-71.79%
Book/sh	1.76	P/B	0.33	EPS next Y	-	ROA	-17.69%	Short Interest	0.07M	Perf Year	-90.47%
Cash/sh	0.08	P/C	7.00	EPS next 5Y	-	ROE	-22.13%	52W Range	0.19 - 14.51	Perf YTD	-86.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	73.53%	ROI	-14.53%	52W High	-95.98%	Beta	1.06
Dividend TTM	-	Quick Ratio	5.34	Sales past 5Y	0.00%	Gross Margin	-	52W Low	215.62%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	5.34	EPS Y/Y TTM	97.56%	Oper. Margin	-	RSI (14)	50.81	Volatility	27.63% 20.49%
Employees	9	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	36.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	93.64%	Payout	-	Rel Volume	0.15	Prev Close	0.63
Sales Surprise	-	EPS Surprise	149.35%	Sales Q/Q	-	Earnings	-	Avg Volume	468.67K	Price	0.58
SMA20	9.93%	SMA50	2.28%	SMA200	-66.99%	Trades		Volume	68,711	Change	-6.83%

Nov-14-24 08:00AM	Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum (GlobeNewswire) -17.24%
Nov-13-24 07:00AM	Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company (GlobeNewswire)
Sep-10-24 07:00AM	Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings (GlobeNewswire)
Aug-23-24 05:00PM	Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q (GlobeNewswire) +5.78%
Jul-31-24 07:00AM	Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program (GlobeNewswire) +6.04%
08:00AM	Loading…
Jul-11-24 08:00AM	Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds (GlobeNewswire)
Jul-09-24 07:00AM	Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium (GlobeNewswire) +17.31%
Jun-27-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -30.23%
06:00AM	Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease (GlobeNewswire)
May-22-24 07:00AM	Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention (GlobeNewswire)
May-20-24 07:00AM	Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference (GlobeNewswire)
May-16-24 07:00AM	First Wave BioPharma Changes Name to Entero Therapeutics (GlobeNewswire)
May-15-24 09:52AM	FWBI Stock Earnings: First Wave BioPharma Beats EPS for Q1 2024 (InvestorPlace)
May-10-24 07:55AM	First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market (GlobeNewswire)
May-09-24 07:00AM	First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month (GlobeNewswire)
09:00AM	Loading…
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-24-24 07:00AM	First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients (GlobeNewswire)
Apr-17-24 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase (GlobeNewswire)
Apr-15-24 07:00AM	First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference (GlobeNewswire)
Apr-05-24 09:55AM	Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-27-24 12:00PM	First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-18-24 07:00AM	First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference (GlobeNewswire)
Mar-14-24 08:05AM	Why Is First Wave BioPharma (FWBI) Stock Up Today? (InvestorPlace) -17.76%
06:00AM	First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline (GlobeNewswire)
Mar-05-24 07:00AM	First Wave BioPharma to Participate In 'Fireside Chat' at the 36th Annual Roth Conference (GlobeNewswire) +11.10%
Mar-04-24 08:00AM	First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering (GlobeNewswire) -23.92%
Feb-13-24 07:00AM	First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024 (GlobeNewswire) -9.11%
Jan-23-24 07:00AM	First Wave BioPharma to Present at the DealFlow MicroCap Conference (GlobeNewswire)
Jan-17-24 07:00AM	First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico (GlobeNewswire)
Jan-04-24 06:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024 (GlobeNewswire)
11:55AM	Loading…
Dec-27-23 11:55AM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced (GlobeNewswire) +49.86%
10:29AM	Why Is First Wave Biopharma (FWBI) Stock Up 148% Today? (InvestorPlace)
06:00AM	First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program (GlobeNewswire)
Dec-20-23 10:03AM	FWBI Stock Earnings: First Wave BioPharma Reported Results for Q1 2023 (InvestorPlace)
10:03AM	FWBI Stock Earnings: First Wave BioPharma Beats EPS for Q3 2023 (InvestorPlace)
Dec-18-23 06:00AM	First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company (GlobeNewswire) -22.14%
Dec-14-23 09:15AM	First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders (GlobeNewswire) -16.78%
Dec-06-23 07:00AM	First Wave BioPharma to Participate in BIO Partnering @JPM During J.P. Morgan Week 2024 (GlobeNewswire)
Dec-05-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference (GlobeNewswire)
Oct-10-23 07:00AM	Date and Time Announced for First Wave BioPharma CEO James Sapirstein's Presentation at the 2023 BIO Investor Forum (GlobeNewswire)
Oct-03-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference (GlobeNewswire)
Sep-15-23 08:45AM	First Wave BioPharma To Present at the BIO Investor Forum (GlobeNewswire) -13.39%
Sep-14-23 10:43AM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) +16.75%
06:00AM	First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi (GlobeNewswire)
Sep-05-23 07:00AM	First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +55.17%
Jul-19-23 08:15AM	First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering (GlobeNewswire)
Jul-13-23 07:00AM	First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation (GlobeNewswire) -32.46%
Jul-05-23 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire)
Jun-28-23 07:00AM	First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire)
Jun-27-23 07:00AM	First Wave BioPharma Strengthens Intellectual Property Estate (GlobeNewswire) -6.51%
Jun-15-23 11:31AM	First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30) (GlobeNewswire) +8.57%
Jun-13-23 12:50PM	First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) +33.12%
07:00AM	First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
May-15-23 07:00AM	First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference (GlobeNewswire)
May-11-23 07:00AM	First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
May-02-23 07:30AM	First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire) -7.14%
Apr-25-23 07:00AM	First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis (GlobeNewswire)
Mar-13-23 08:00AM	First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -16.76%
07:00AM	HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors (GlobeNewswire)
Mar-10-23 07:00AM	First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis (GlobeNewswire)
Mar-09-23 07:00AM	First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire) +6.48%
Feb-28-23 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the 35th Annual Roth Conference (GlobeNewswire)
Feb-21-23 07:00AM	First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference (GlobeNewswire) +7.14%
Feb-13-23 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire) -6.30%
Feb-07-23 07:00AM	First Wave BioPharma Regains Compliance With Nasdaqs Minimum Bid Price Requirement (GlobeNewswire)
Feb-02-23 07:00AM	First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis (GlobeNewswire) +5.03%
Jan-31-23 07:00AM	First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis (GlobeNewswire) -7.51%
Jan-30-23 07:00AM	First Wave BioPharma to Present at the BIO CEO & Investor Conference (GlobeNewswire) +7.92%
Jan-25-23 07:00AM	First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio (GlobeNewswire) +22.17%
Jan-24-23 07:00AM	First Wave BioPharma to Present at Sequire Biotechnology Conference (GlobeNewswire)
Jan-13-23 04:00PM	First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency (GlobeNewswire) -11.99%
10:20AM	First Wave BioPharma Announces Results of Special Meeting of Stockholders (GlobeNewswire)
Jan-09-23 09:10AM	First Wave BioPharma Announces Adjournment of Special Meeting (GlobeNewswire) -13.33%
Jan-05-23 09:45AM	ZyVersa Therapeutics Appoints Three New Board Members (PR Newswire)
Dec-12-22 07:30AM	First Wave BioPharma to Participate in BIO Partnering @ JPM During J.P. Morgan Week 2023 (GlobeNewswire)
Dec-05-22 07:00AM	First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase (GlobeNewswire)
Nov-30-22 07:00AM	First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase (GlobeNewswire) +5.60%
Nov-25-22 05:45PM	First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock (GlobeNewswire) +16.91%
Nov-22-22 04:15PM	First Wave BioPharma, Inc. Announces Closing of Private Placement (GlobeNewswire)
Nov-21-22 08:00AM	First Wave BioPharma, Inc. Announces Private Placement (GlobeNewswire) -11.61%
Nov-16-22 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire)
Oct-31-22 07:00AM	First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation (GlobeNewswire)
Oct-11-22 05:30PM	First Wave BioPharma, Inc. Announces Closing of $6.0 Million Public Offering (GlobeNewswire)
Oct-10-22 07:00AM	First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360 (GlobeNewswire)
Oct-06-22 09:00PM	First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering (GlobeNewswire) -11.96% -6.17%
08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews James Sapirstein CEO, First Wave BioPharma, Inc. (ACCESSWIRE)
Sep-28-22 07:00AM	First Wave BioPharmas CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference (GlobeNewswire)
Sep-19-22 07:00AM	First Wave BioPharma Chairman and CEO Issues Letter to Stockholders (GlobeNewswire) -9.25%
Sep-14-22 07:00AM	First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference (GlobeNewswire) -12.15%
Sep-07-22 07:00AM	First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation (GlobeNewswire) -23.22%
Aug-31-22 07:00AM	First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract (GlobeNewswire) -5.54%
Aug-29-22 07:00AM	First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022 (GlobeNewswire)
Aug-25-22 12:00PM	First Wave BioPharma, Inc. Announces Reverse Stock Split (GlobeNewswire) -18.18%
Jul-15-22 08:00AM	First Wave BioPharma, Inc. Announces Private Placement (GlobeNewswire) -21.38%
May-17-22 07:00AM	First Wave BioPharma to Participate in Fireside Chat at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.94%
Apr-29-22 04:30PM	First Wave BioPharma Chairman and CEO Issues Letter to Shareholders (GlobeNewswire) -35.42%
Apr-27-22 07:00AM	First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio (GlobeNewswire)
Mar-31-22 08:15AM	Goldman Small Cap Research Publishes New Research Report on First Wave BioPharma, Inc. (ACCESSWIRE)
Mar-28-22 04:23PM	First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19 (GlobeNewswire)
Mar-22-22 07:00AM	First Wave BioPharma to Participate in Maxims 2022 Virtual Growth Conference (GlobeNewswire)

Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Romano Sarah	Chief Financial Officer	Oct 09 '24	Sale	0.45	476	212	18,014	Oct 10 05:00 PM
Romano Sarah	Chief Financial Officer	Jul 02 '24	Sale	1.07	621	664	18,490	Jul 03 02:34 PM
SAPIRSTEIN JAMES	Chairman and CEO	Jul 02 '24	Sale	1.07	1,289	1,379	35,816	Jul 03 02:33 PM
SAPIRSTEIN JAMES	Chairman and CEO	Apr 01 '24	Sale	4.23	174	736	37,105	Apr 03 05:14 PM
Romano Sarah	Chief Financial Officer	Apr 01 '24	Sale	4.23	75	317	19,111	Apr 03 05:13 PM
SAPIRSTEIN JAMES	Chairman and CEO	Mar 15 '24	Sale	4.96	1,887	9,360	37,279	Mar 19 04:13 PM
Romano Sarah	Chief Financial Officer	Mar 15 '24	Sale	4.96	1,120	5,555	19,186	Mar 19 04:10 PM
Romano Sarah	Chief Financial Officer	Jan 12 '24	Sale	4.20	98	412	20,306	Jan 17 04:02 PM
SAPIRSTEIN JAMES	Chairman, President and CEO	Jan 12 '24	Sale	4.20	166	697	39,166	Jan 17 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTO

Entero Therapeutics Inc

Upgrade your FINVIZ experience